Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹112 Cr
verification pending
Revenue YoY
16.6%
reported change
EBITDA
₹42.1 Cr
latest reported figure
Source
bse pending
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Vimta Labs delivered a strong Q4 FY26 with revenue of ₹112 crore (+16.6% YoY) and EBITDA of ₹42.1 crore (+21.5% YoY), driven by robust performance in pharma and food testing. EBITDA margin expanded to 37.6% (+150 bps YoY), among the best in the industry. The company entered biologics CRD services, with infrastructure ready and client discussions underway. Management targets maintaining 20-25% revenue CAGR and sustaining margins around 35%, though near-term headwinds from geopolitical tensions and input cost inflation pose risks. The balance sheet remains net debt-free with ₹65 crore cash. Key risk: any escalation in global trade disruptions could impact client spending and delay growth.
Colored figures show movement against the previous available record.
Guidance to track
- Management targets maintaining historical CAGR of 20-25% annually, aiming for ₹500 crore revenue run-rate.
- Management expects EBITDA margin to sustain in the 35% range, with possible 1-2% correction due to input cost and manpower inflation.
- Infrastructure and team are ready; initial projects expected from domestic clients, with international traction building.
Risks flagged
- The Iran-US war has increased consumable costs and lead times, impacting margins and operations.
- Electronics and electrical testing segment faced leadership challenges and did not meet expectations; recovery is uncertain.
- Early biologics projects may have lower margins due to high input costs and domestic client mix; global ramp-up is unproven.
Key quotes
- Our focus remains on sustaining margins in a stable and competitive range over the medium term.
- The purpose of undertaking this is to be closer to our customers because we have a sizable population there and also to give them greater confidence.
- We have good inquiries and we will be closing them soon. We have a good traction from Europe, from India, a couple of them from US as well.
Research modules